Back to Screener

Belite Bio, Inc American Depositary Shares (BLTE)

Price$158.05

Favorite Metrics

Price vs S&P 500 (26W)112.21%
Price vs S&P 500 (4W)-1.22%
Market Capitalization$6.87B

All Metrics

Book Value / Share (Quarterly)$4.55
P/TBV (Annual)13.25x
Indicated Dividend (Annual)$0.00
Price vs S&P 500 (YTD)2.86%
EPS (TTM)$-1.55
10-Day Avg Trading Volume0.16M
EPS Excl Extra (TTM)$-1.55
EPS (Annual)$-1.18
ROI (Annual)-24.79%
Cash / Share (Quarterly)$4.56
ROA (Last FY)-23.76%
EBITD / Share (TTM)$-1.56
ROE (5Y Avg)-34.27%
Cash Flow / Share (Annual)$-0.92
P/B Ratio47.16x
P/B Ratio (Quarterly)17.72x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-574.00x
ROA (TTM)-31.55%
EPS Incl Extra (Annual)$-1.18
Current Ratio (Annual)24.31x
Quick Ratio (Quarterly)24.09x
3-Month Avg Trading Volume0.21M
52-Week Price Return187.94%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.58
52-Week High$200.00
EPS Excl Extra (Annual)$-1.18
26-Week Price Return116.19%
Quick Ratio (Annual)24.09x
13-Week Price Return9.03%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)24.31x
Enterprise Value$6,871.236
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.56
3-Month Return Std Dev47.37%
Net Income / Employee (TTM)$-2
ROE (Last FY)-24.79%
EPS Basic Excl Extra (Annual)$-1.18
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.55
ROI (TTM)-32.86%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.58
Price vs S&P 500 (52W)158.11%
Year-to-Date Return5.50%
5-Day Price Return-6.85%
EPS Normalized (Annual)$-1.18
ROA (5Y Avg)-32.16%
Month-to-Date Return5.85%
EBITD / Share (Annual)$-1.30
ROI (5Y Avg)-34.21%
EPS Basic Excl Extra (TTM)$-1.55
P/TBV (Quarterly)13.25x
P/B Ratio (Annual)13.25x
Book Value / Share (Annual)$4.58
Price vs S&P 500 (13W)8.34%
Beta-1.16x
Revenue / Share (TTM)$0.00
ROE (TTM)-32.86%
52-Week Low$53.59

Industry Peers — Pharmaceuticals(309)

SymbolP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
BLTEBelite Bio, Inc American Depositary Shares
$158.05
LLYEli Lilly & Co.
13.08x44.70%83.04%27.59%$903.99
JNJJohnson & Johnson
5.94x7.87%67.95%14.90%$234.54
ABBVABBVIE INC.
6.04x8.57%71.62%-2.88%$208.99
MRKMerck & Co., Inc.
4.41x1.31%78.55%21.23%$115.46
AZNAstraZeneca PLC
5.28x8.63%81.31%21.88%$200.47
NVSNovartis AG
4.98x8.91%75.82%15.26%$149.73
NVONovo-Nordisk A/S
3.62x6.43%80.98%20.66%$40.93
ABTAbbott Laboratories
3.66x6.59%56.50%8.20%$95.47
PFEPfizer Inc.
2.47x-1.64%75.81%-3.51%$27.22
BMYBristol-Myers Squibb Co.
2.47x-0.22%72.63%$58.96

About

Belite Bio is a clinical-stage biopharmaceutical company developing novel therapeutics for retinal degeneration and metabolic diseases. Its pipeline includes treatments for age-related macular degeneration, Stargardt disease, nonalcoholic fatty liver disease, type 2 diabetes, and gout.